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Abstract
Background: Regular participation in physical activity by people with cystic fibrosis (CF) promotes positive clinical and
health outcomes including reduced rate of decline in lung function, fewer hospitalizations and greater wellbeing.
However adherence to exercise and activity programs is low, in part due to the substantial daily therapy burden for
young people with CF. Strict infection control requirements limit the role of group exercise programs that are
commonly used in other clinical groups. Investigation of methods to promote physical activity in this group has been
limited. The Active Online Physical Activity in Cystic fibrosis Trial (ActionPACT) is an assessor-blinded, multi-centre,
randomized controlled trial designed to compare the efficacy of a novel web-based program (ActivOnline) compared
to usual care in promoting physical activity participation in adolescents and young adults with CF.
Methods: Adolescents and young adults with CF will be recruited on discharge from hospital for a respiratory
exacerbation. Participants randomized to the intervention group will have access to a web-based physical activity
platform for the 12-week intervention period. ActivOnline allows users to track their physical activity, set goals, and self-
monitor progress. All participants in both groups will be provided with standardised information regarding general
physical activity recommendations for adolescents and young adults.
Outcomes will be assessed by a blinded assessor at baseline, after completion of the intervention, and at 3-months
followup. Healthcare utilization will be assessed at 12months from intervention completion. The primary outcome is
change in moderate-to-vigorous physical activity participation measured objectively by accelerometry. Secondary
outcomes include aerobic fitness, health-related quality of life, anxiety and depression and sleep quality.
Discussion: This trial will establish whether a web-based application can improve physical activity participation more
effectively than usual care in the period following hospitalization for a respiratory exacerbation. The web-based
application under investigation can be made readily and widely available to all individuals with CF, to support physical
activity and exercise participation at a time and location of the user’s choosing, regardless of microbiological status.
Trial registration: Clinical trial registered on July 13, 2017 with the Australian and New Zealand Clinical Trials Register
at (ACTRN12617001009303).
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Background
Cystic Fibrosis (CF) is a complex, multi-system inherited
disorder. This progressive disorder is commonly charac-
terised by chronic suppurative lung disease, including
bronchiectasis, progressing to respiratory failure [1].
People with CF require repeated admission to hospital
to treat respiratory complications; have poor quality of
life and life expectancy; experience reduced aerobic fit-
ness and physical functioning, and increased prevalence
of anxiety and depression [2]. Higher levels of physical
activity participation and aerobic fitness have been asso-
ciated with improved health outcomes, in particular a
slower decline in lung function [3], reduced need for
hospitalization [4], and improved prognosis [5] in both
children and adults with CF.
Regular participation in moderate-to-vigorous intensity
physical activity (MVPA) has numerous health benefits in-
cluding improved aerobic fitness and bone density, and re-
duced risk of depression [6]. Regular exercise and physical
activity are recommended in CF treatment guidelines [2],
to improve aerobic fitness; relieve breathlessness; and
positively influence bone accretion, blood glucose control
and clearance of pulmonary secretions [7, 8]. Despite the
benefits of regular physical activity participation, people
with CF demonstrate poor uptake and adherence to pro-
grams designed to augment physical activity and exercise
[9]. This problem is compounded by the limited range of
methods trialled to date to increase physical activity par-
ticipation by people with CF [10].
Few strategies have been applied in the promotion of
physical activity to people with CF. A Cochrane Review of
strategies to promote physical activity participation by
people with CF identified several studies which employed
various forms of exercise training to improve physical ac-
tivity, in mostly young people with mild CF lung disease
[3, 10–13]. No study in the review investigated the effect
of strategies such as motivational interviewing or the use
of technology or telemedicine in promoting physical activ-
ity participation by people with CF. There is limited evi-
dence that interventions of medium-longer term duration,
with a requirement for self-directed participation, may be
more effective than short-term, supervised training in
improving physical activity participation [10].
Technology and telemedicine applications have the po-
tential to create new ways to promote and support phys-
ical activity and exercise participation in this population,
and are feasible and acceptable to people with CF [14, 15].
Importantly, no physical activity intervention study in
people with CF to date has focussed on the period imme-
diately post hospitalization. Objectively measured physical
activity levels in adolescents and young adults with CF
have been found to decline by over 50% in the first one
month following hospital discharge [4]. In other popula-
tions with chronic respiratory disease, particularly people
with chronic obstructive pulmonary disease (COPD), fail-
ure to recover physical activity levels in the month follow-
ing hospital discharge is associated with an increased
likelihood of hospital readmission [16]. Whether a web-
based intervention to promote physical activity can effect-
ively improve activity participation, and delay time to next
admission, in young people with CF is unknown.
This paper describes the protocol for a randomized con-
trolled trial testing a web-based application to promote
physical activity in adolescents and young adults with CF.
The aims of the trial are to: 1) investigate the effect of a
web-based application (ActivOnline) to promote physical
activity participation in young people with CF; 2) assess the
effect of a technology based intervention (ActivOnline), in
the period immediately following hospital discharge on
aerobic fitness, lung function, quality of life, anxiety and
depression, sleep quality, and healthcare utilisation in
young people with CF. We hypothesise that the web-based
intervention will improve uptake and participation in phys-
ical activity by young people with CF following a hospital
admission for a respiratory exacerbation compared to usual
care; that increased physical activity participation will lead
to improvements in exercise capacity, lung function, qual-
ity of life, anxiety and depression, and sleep quality; and
that healthcare utilization will be reduced in the interven-
tion group over 12months.
Methods
Design
A randomized, controlled, assessor-blinded trial will be
conducted at eight Australian sites (Alfred Health,
Monash Health and Royal Children’s Hospital, Victoria;
Royal Hobart Hospital, Tasmania; Royal Prince Alfred
Hospital, Westmead Hospital and Children’s Hospital at
Westmead, New South Wales; Royal Adelaide Hospital,
South Australia). The Human Research Ethics Commit-
tee at Alfred Health approved the study for all sites, and
local governance approvals were obtained from all par-
ticipating sites. The trial was registered at www.anzctr.
org.au (ACTRN12617001009303) on July 13, 2017. This
trial protocol employs our established methods with re-
spect to randomization procedures, data integrity and
management, trial safety monitoring and managing par-
ticipant withdrawals [17].
Participants and recruitment
Potential participants will be all individuals with CF ad-
mitted to hospital for a respiratory cause at the participat-
ing sites. To be eligible for inclusion participants will: 1)
have a confirmed diagnosis of CF; 2) be aged 12–35 years
(inclusive); and 3) have access to the internet via a com-
puter or mobile device. Potential participants will be ex-
cluded if they: 1) have a severe co-morbidity limiting
mobilisation or physical activity participation (e.g.
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orthopedic, cardiac or neurological condition); 2) have
been the recipient of a lung transplant; 3) are pregnant; or
4) they (or their parents) are unable to provide informed
consent.
Randomisation
Participants will be randomly allocated (1:1) to ‘usual care’
or the ‘ActivOnline’ intervention. A computer-generated,
block randomization scheme will be used with stratification
for 1) site of recruitment – to allow for differences in local
treatment practices including those related to usual pre-
scription of exercise, and 2) whether or not the participant
is enrolled in fulltime schooling (primary or secondary ver-
sus not in fulltime schooling) as the time of transition from
secondary school to university or the workforce is a known
time for decline in physical activity participation [18].
Sequence generation will be performed by an individual
who is independent of the research team and randomization
will occur using an online database. The randomization
sequence will be concealed from investigators. Participants
will be allocated to groups after completion of one week of
physical activity monitoring immediately following discharge
from hospital. Participants will not be blind to the
intervention, however all outcomes will be measured by
an independent assessor blind to group allocation. The
flow of participants through the study will be reported
according to the recommendations of the Consolidated
Standard of Reporting Trials (CONSORT) [19].
Interventions
Usual care
Physical activity and exercise is routinely advised for all
patients with CF [20, 21]. All participants will be provided
with age-appropriate information regarding recommended
guidelines for physical activity participation. Participants
will be referred to a free online resource (http://www.nhs.
uk/Livewell/fitness/Pages/physical-activity-guidelines-for-
young-people.aspx) containing guidelines and information
regarding amount and intensity of daily physical activity
participation [6]. Physical activities which involve the use
of large muscle groups continuously will be encouraged
[3], as will the preferred activities of the participants [11].
ActivOnline intervention
Participants randomized to the active intervention group
will be given individualized access to the ActivOnline
program (www.activonline.com.au) and encouraged to
use this for the 12-week intervention period, to track
their physical activity, set goals, and self-monitor pro-
gress. This will be in addition to usual care.
ActivOnline uses principles of motivational interview-
ing and cognitive behavioural strategies, with the aim of
increasing opportunity and motivation for physical activ-
ity participation. It provides a secure portal for recording
and reviewing physical activity and exercise participation
details. ActivOnline is a mobile platform accessible from
any internet browser across a variety of devices including
tablets and smartphones. When logging into ActivOn-
line participants will be prompted to set weekly exercise
and physical activity goals, as well as to record details of
their physical activity or exercise sessions including total
time and step count. To support recording of daily step
count participants may use their own activity tracker
(e.g. Fitbit) or mobile telephone. A pedometer (Yamax
digiwalker SW500, Yamasa Tokei Keiki Co., Ltd., Tokyo,
Japan) will be provided to participants on request. Data
entered into ActivOnline are displayed in numerical and
graphical form to allow visualization of progress over
time (see Fig. 1). Participants can choose the frequency
of use of ActivOnline, as data can be entered retrospect-
ively. If no activity has been logged for three days, a
standardized alert message will be issued by the Acti-
vOnline program and emailed to the participant.
Participants in the intervention group will also be able
to communicate with research clinicians directly via the
messaging system contained within ActivOnline about
the trial or their clinical status, should they require. The
number and nature of contacts via the messaging system
will be recorded.
Outcome measures
Demographic details of age, gender, body mass index
(BMI) and lung function will be collected at baseline,
prior to hospital discharge. Details pertaining to CF
genotype, age at diagnosis and status for pancreatic in-
sufficiency will be obtained from the medical record.
Frequency of access to the ActivOnline program and
number of exercise sessions recorded will be extracted
from ActivOnline.
Participants will undertake assessment of clinical out-
come measures at baseline, end intervention and after 3
months follow-up (Fig. 2). The following measures will
be recorded:
Primary outcome
The primary outcome will be time spent in moderate-
vigorous physical activity (MVPA) as measured object-
ively using accelerometry. The intensity of physical activ-
ity will be monitored using a wrist-worn accelerometer
provided to participants for seven days (Actigraph Link;
Actigraph LLC, Pensacola, FL 32502 USA). This triaxial
accelerometer is validated for the assessment of free-
living activity and is a recommended device for the ob-
jective assessment of physical activity in individuals with
CF [22]. The a priori definition for activity monitoring
data to be included in the final analysis is a minimum of
three days [23], for ≥10 h of valid wear time in each day
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[4]. Average time (minutes) per day spent in MVPA will
be reported.
Accelerometers will be initialized (sampling rate 100Hz)
and downloaded using the ActiLife software (v6.10.4; Acti-
Graph, Pensacola, Fl, USA). Wear-time will be established
using ActiLife parameters such that a period of at least 90
min of consecutive activity counts of zero, with a spike
threshold of two minutes and 100 counts per minute, will
define non-wear time [24]. Pre-specified cut-points will be
used to determine time spent in at least moderate intensity
activity, with activity intensity thresholds determined by
participant age [25, 26].
Secondary outcomes
– Self-reported physical activity participation will also be
assessed using the Habitual Activity Estimation Scale
(HAES), a validated subjective measure of physical
activity participation in young people with CF [27].
Two measures of physical activity participation will
allow for comparison between patient perception of
activity intensity and objectively measured data.
– Aerobic fitness will be assessed using the Modified
Shuttle Test (25 level version; MST-25) [28], an
extension of a field test of aerobic capacity which is
a reliable and valid measure of exercise capacity in
adults and children with CF [29–31]. The MST-25
is a symptom-limited estimated assessment of peak
aerobic capacity with distance covered the outcome
of interest. It requires participants to walk, or run as
necessary, around two markers over a 10-m course
in time with a pre-recorded audio signal. Each level
of the test lasts for one minute, with the speed
Fig. 1 ActivOnline. a: ActivOnline website homepage; b-d: ActivOnline data entry portal – data entry screen (b); real time graphical display of
data (c); goal setting (d). The image depicted in (a) is legally sourced royalty free stock photo from Adobe Stock
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increasing by 0.61 km/hr each minute. Participants
cease the test when they feel they are no longer able
to continue or when they fail to meet the course
marker on two consecutive shuttles [29].
– Assessment of the reasons underlying participants
decision to engage, or not engage, in physical
exercise will be undertaken using the Behavioural
Regulation in Exercise Questionnaire (BREQ-2) [32].
The BREQ-2 has been used in young people [33]
and adults [34] with a variety of chronic medical
and psychological conditions.
– Spirometry measures of forced expiratory volume in
one second (FEV1) and forced vital capacity (FVC)
will be reported. Spirometry measures will be
conducted according to American Thoracic Society/
European Respiratory Society (ATS/ERS) standard
procedures [35].
– Health-related quality of life (HRQoL) will be
assessed using the revised edition of the Cystic
Fibrosis Questionnaire (CFQ-R) [36]. The CFQ-R is
a valid and reliable tool that provides a disease-
specific measure of HRQoL [36].
– Anxiety and depression will be evaluated using the
Hospital Anxiety and Depression Scale (HADS) [37]
and the Center for Epidemiologic Studies -Depression
(CES-D) scale [38]. These scales have been used in
establishing the prevalence of anxiety and depression
in young people and adults with CF [39].
– As exercise can positively impact both sleep and
health outcomes, participants will complete the
Pittsburgh Sleep Quality Index (PSQI) [40] self-
report measure of sleep quality. The PSQI has been
validated widely, and previously used in children and
young adults with CF [41].
– Healthcare utilization will be documented from the
medical record. Time to next hospital admission and
the number of hospital days up to 12months following
completion of the intervention period will be reported.
Analysis
Sample size
To detect a difference of 20-min per day in MVPA
participation between ActivOnline and control groups
following the intervention period, a total of 56 partici-
pants will be required. This sample size was based on
physical activity participation measured post hospitalisa-
tion in our population of young adults with CF [4] and
assumes a standard deviation of 26 [4] with a power of
80% and a significance level of p < 0.05. It was planned
to randomize a total of 75 participants to allow for 25%
attrition. Over the first 18 months of recruitment there
was higher than anticipated attrition for the primary
outcome. It was decided to extend recruitment beyond
the initial target of 75 to account for this attrition. The
original trial registration incorrectly stated a different
number of participants (incorrect total 150). This was
Fig. 2 Participant schedule. MVPA =moderate-vigorous physical activity; MST-25 =Modified shuttle test (25 levels); CFQR = Cystic Fibrosis quality
of life questionnaire – revised; HADS = Hospital anxiety and depression scale; CES-D = Centre for epidemiological studies depression scale; HAES =
Habitual activity estimation scale; PSQI = Pittsburgh Sleep Quality Index; FEV1 = Forced expiratory volume in one second
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due to an error in interpreting the sample size calcula-
tion. The correct number of participants required (total
for both groups combined) is n = 56, with n = 19 to
allow for 25% attrition, giving a correct total sample size
of n = 75. In our original registration we had incorrectly
assumed that n = 56 were required in each group.
Analysis
Continuous variables will be analysed by fitting linear
mixed models, controlling for recruitment centre and
baseline values as required. The proportion of partici-
pants who achieve age recommended physical activity
will be compared between groups using a chi-squared
test. Time to hospital admission will be evaluated using
Kaplan-Meier curves and Cox proportional hazards
modeling. All data will be analysed by intention-to-treat.
Alpha will be set at 0.05.
Data integrity and management
Data will be stored on a purpose-built online database
(www.adeptrs.com), with encryption, password-protection
and restricted access. No identifying information will be
stored in the online database.
Withdrawal
A participant will be considered to have withdrawn from
the study when consent is revoked. If this occurs, no
further assessments will be performed. Participants
will be informed that data collected up to the time of
withdrawal will form part of the study results unless
permission is expressly declined. Withdrawn partici-
pants will not be replaced. Protocol violations will not
constitute grounds for withdrawal. Study withdrawal
will not have any impact on care provided by any of
the participating sites.
Monitoring
The trial will be monitored by an independent Data Safety
Monitoring Board (DSMB) comprising a respiratory phys-
ician and two clinical research physiotherapists, with consult-
ation with a statistician as required. The DSMB will review
data relating to the primary outcome (MVPA participation),
as well as quality of life and safety. Data will be presented to
the DSMB in a blinded fashion. The DSMB will initially re-
view data at a time six months from the commencement of
recruitment, and six monthly thereafter. Any serious adverse
events will be notified immediately to the overseeing ethics
committee (Alfred Health) and the relevant site governance
committee, as well as to the DSMB. If there are concerns
about the safety of participants, the DSMB will make a rec-
ommendation to the trial steering committee about continu-
ing, stopping, or modifying the trial.
Discussion
Regular physical activity is a key recommended compo-
nent of international care guidelines for individuals with
CF [20, 21], yet only limited methods for supporting pa-
tients to adhere to this component of their therapeutic
regimen have been investigated. This study will compare
the effects of a web-based platform which enables activ-
ity tracking, self-monitoring and goal setting, compared
to usual care on clinical outcomes and healthcare
utilization in adolescents and young adults with CF.
Internationally, annual medical expenditure on individ-
uals with CF is 22 times greater than those without CF
[42]. Physical activity participation is a low-cost treatment
strategy that has the potential to reduce the impact and
progression of chronic lung disease in CF, and associated
healthcare expenditure. To date, few strategies outside of
exercise training programs have been explored as means to
promote daily physical activity participation by people with
CF [10]. The physical activity promotion strategy under in-
vestigation addresses key therapy delivery issues associated
with treatment timing and infection control. By providing
opportunity for goal-setting and self-monitoring, at a time
and place convenient to the patient, challenges of adher-
ence to exercise programs and maintenance of activity fol-
lowing hospitalisation might be reduced.
Trial status
Recruitment commenced in September 2017 and re-
mains ongoing.
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